Monte Rosa Therapeutics, Inc. (GLUE)
16.48
-0.08
(-0.48%)
USD |
NASDAQ |
Dec 12, 10:40
Monte Rosa Therapeutics Cash from Investing (Quarterly): 38.14M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Novartis AG | -858.23M |
| AVITA Medical, Inc. | -5.275M |
| NanoVibronix, Inc. | -0.028M |
| Mirum Pharmaceuticals, Inc. | -2.227M |
| Day One Biopharmaceuticals, Inc. | 13.46M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 100.43M |
| Cash from Financing (Quarterly) | 0.348M |
| Free Cash Flow | 145.02M |
| Free Cash Flow Per Share (Quarterly) | 1.211 |
| Free Cash Flow to Equity (Quarterly) | 100.74M |
| Free Cash Flow to Firm (Quarterly) | 99.78M |
| Free Cash Flow Yield | 11.39% |